EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identifying the Reactive Metabolites of Tyrosine Kinase Inhibitor Pexidartinib In Vitro Using LC–MS-Based Metabolomic Approaches

Xuan Qin iD, Yong Wang, Kevin R MacKenzie, John M Hakenjos, Si Chen, Saleh M Khalil, Sung Yun Jung iD, Damian W Young, Lei Guo, Feng Li iD

Chemical Research in Toxicology · 2023

DOI: 10.1021/acs.chemrestox.3c00164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Research in Toxicology, 2023. Verfasst von Xuan Qin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Discovery, Department of Pathology & Immunology, Baylor College of Medicine, Houston, Texas 77030, United States. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pexidartinib (PEX, TURALIO), a selective and potent inhibitor of the macrophage colony-stimulating factor-1 receptor, has been approved for the treatment of tenosynovial giant cell tumor. However, frequent and severe adverse effects have been reported in the clinic, resulting in a boxed warning on PEX for its risk of liver injury. The mechanisms underlying PEX-related hepatotoxicity, particularly metabolism-related toxicity, remain unknown. In the current study, the metabolic activation of PEX was investigated in human/mouse liver microsomes (HLM/MLM) and primary human hepatocytes (PHH) using glutathione (GSH) and methoxyamine (NH2OMe) as trapping reagents. A total of 11 PEX-GSH and 7 PEX-NH2OMe adducts were identified in HLM/MLM using an LC-MS-based metabolomics approach. Additionally, 4 PEX-GSH adducts were detected in the PHH. CYP3A4 and CYP3A5 were identified as the primary enzymes responsible for the formation of these adducts using recombinant human P450s and CYP3A chemical inhibitor ketoconazole. Overall, our studies suggested that PEX metabolism can produce reactive metabolites mediated by CYP3A, and the association of the reactive metabolites with PEX hepatotoxicity needs to be further studied.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP3AChemical and Drug Induced Liver InjuryMiceHumansAnimalsChromatography, LiquidTyrosine Kinase InhibitorsTandem Mass SpectrometryProtein Kinase InhibitorsCytochrome P-450 CYP3A InhibitorsMicrosomes, LiverMetabolomicsGlutathioneAminopyridinesPyrroles

Substanzen

Cytochrome P-450 CYP3ATyrosine Kinase InhibitorsProtein Kinase InhibitorsCytochrome P-450 CYP3A InhibitorsGlutathionepexidartinibAminopyridinesPyrroles

Autor:innen und Institutionen

  • Center for Drug Discovery, Department of Pathology & Immunology, Baylor College of Medicine, Houston, Texas 77030, United States.
  • NMR and Drug Metabolism Core, Advanced Technology Cores, Baylor College of Medicine, Houston, Texas 77030, United States.
  • Department of Pharmacology & Chemical Biology, Baylor College of Medicine, Houston, Texas 77030, United States.
  • Division of Biochemical Toxicology, National Center for Toxicological Research/U.S. Food and Drug Administration (FDA), Jefferson, Arkansas 72079, United States.
  • Department of Molecular & Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, United States.

ORCID-Profile: Xuan Qin, Sung Yun Jung, Feng Li

Förderung

  • NICHD NIH HHS
  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Bill and Melinda Gates Foundation
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development

Zitieren

APA

Qin, X., Wang, Y., MacKenzie, K. R., Hakenjos, J. M., Chen, S., Khalil, S. M., Jung, S. Y., Young, D. W., Guo, L., & Li, F. (2023). Identifying the Reactive Metabolites of Tyrosine Kinase Inhibitor Pexidartinib In Vitro Using LC–MS-Based Metabolomic Approaches. Chemical Research in Toxicology. https://doi.org/10.1021/acs.chemrestox.3c00164

Vancouver

Qin X, Wang Y, MacKenzie KR, Hakenjos JM, Chen S, Khalil SM, et al. Identifying the Reactive Metabolites of Tyrosine Kinase Inhibitor Pexidartinib In Vitro Using LC–MS-Based Metabolomic Approaches. Chemical Research in Toxicology. 2023. doi:10.1021/acs.chemrestox.3c00164

BibTeX
@article{Qin2023,
  author = {Qin, Xuan and Wang, Yong and MacKenzie, Kevin R and Hakenjos, John M and Chen, Si and Khalil, Saleh M and Jung, Sung Yun and Young, Damian W and Guo, Lei and Li, Feng},
  title = {Identifying the Reactive Metabolites of Tyrosine Kinase Inhibitor Pexidartinib In Vitro Using LC–MS-Based Metabolomic Approaches},
  journal = {Chemical Research in Toxicology},
  year = {2023},
  doi = {10.1021/acs.chemrestox.3c00164}
}
Kostenlos starten →